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1. Introduction 
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Surgery is 
a possible curative treatment, but most symptomatic HCC cases are in advanced stage 
where surgical resection is not possible. For this group of patients, the prognosis after any 
kind of therapy remains unsatisfactory due to high relapse rate (Llovet et al., 2003). Studies 
were rigorously conducted to tackle various obstacles in treating HCC, putting the focuses on 
targeting cancer cells that either disseminated from the tumor origin, or escaped from 
therapeutic effects. Recently, a multikinase inhibitor sorafenib was approved by FDA for the 
treatment of advanced HCC patients. It marks a major advance in the field as the first 
efficacious targeted therapy for HCC. The primary molecular targets of sorafenib include 
vascular endothelial factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR) 
and Raf (Wilhelm et al., 2004). Although it significantly prolongs both patient survival and the 
time to progression, its overall survival benefit is modest (Llovet et al., 2008).  
Other HCC associated targets, such as epidermal growth factor (EGF) signaling (Hampton, 
2007), telomerase (Djojosubroto et al., 2005) and cyclooxygenase (Márquez-Rosado et al, 2005), 
were studied intensively with regard to their therapeutic effects. However, the benefits are far 
from satisfactory, so there is still a need to identify new therapeutic targets. The exploration of 
new targets against HCC involves multiple disciplines including hepatology, oncology, 
pathology and molecular studies. Increasing number of therapeutic targets which play crucial 
roles in HCC were identified. Identification of new targets not only improves the current HCC 
therapeutic modality, but also drives a deeper understanding of HCC that allows personalized 
treatment in the future. In this chapter, we will briefly review the novel molecular and cellular 
players that contribute to HCC tumorigenesis and progression, and evaluate their potential as 
additional therapeutic targets. 
2. Growth receptor signaling 
The studies of sorafenib administration and other growth signaling inhibitors demonstrated 
the prowess of targeting growth signalings such as epidermal growth factor (EGF), VEGF 
and PDGF pathways. In HCC, many other growth signalings were identified that markedly 
contributes to tumorigenesis and pathogenesis. They include insulin-like growth factor 
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signaling and mTOR pathway, and numerous studies suggested these pathways can be the 
targets against HCC. 
2.1 Insulin-like growth factor signaling 
The insulin-like growth factor (IGF) signaling pathway is frequently dysregulated in HCC. 
The activation of IGF signaling can be established in malignant cells through an autocrinal 
route when the activated signaling is induced by an overexpressed IGF ligand in HCC cells 
(Nussbaum et al., 2008). Insulin-like growth factor 2 (IGF-2) is increased after an 
inflammatory response to liver damage or viral transactivation (Feitelson et al., 2004), and it 
is the major ligand contributing to the increased IGF activity in HCC. IGF-2-mediated 
induction of IGF signaling is prevalent in human HCC, where IGF-2 is overexpressed in 16-
40%, whilst the level of competitive receptor for IGF-2 is decreased in around 80% 
(Whittaker et al., 2010). As such, IGF receptor-ligand binding is enhanced, and subsequent 
downstream signaling is activated in cancer cells. Activation of IGF signaling in HCC cells is 
associated with increase of cell proliferation rate (Schirmacher et al, 1992). While RNAi-
mediated knockdown of IGF-2 could reduce the cell proliferation and induce apoptosis in 
HCC cells, small molecule inhibiting IGF-2-dependent IGF signaling was able to impair the 
growth of HCC cells and retard tumour growth in mice xenograft (Lund et al., 2004).  
Altered IGF-2 bioavailability is another reason for the hyperactivation of IGF signaling in 
HCC. Normally, circulating IGF-2 is bound by IGF-binding protein (IGFBP) so that the 
efficiency of ligand-receptor binding is lowered. In HCC, members of IGFBPs are 
downregulated so that less IGF-2 is sequestrated which allow uncontrolled IGF-2-receptor 
interaction (Hanafusa et al, 2002). Hence, reducing the level of IGF-2 in circulation is another 
valid approach to abrogate the IGF signaling. Re-introduction of recombinant human 
IGFBP-3 was tested and showed potent effect in lowering the activity of IGF-2 (Aishima et 
al., 2006). IGFBP-3 was able to inhibit cancer cell growth and attenuate mitogenic activity of 
HCC cells. It is also reported that IGFBP-3 decreased the phosphorylation and activity of 
numerous pro-tumorigenic proteins such as IRS-1, MAPK, Elk-1, Akt-1 and 
phosphatidylinositol 3'-kinase (Huynh et al., 2002). 
In addition, inhibition of IGF signaling can also be achieved by disrupting other players 
along the IGF signaling axis. IGF signal transduction is mediated by the Insulin receptor, 
IGF-IR and a hybrid of both receptors. In HCC, there is detectable level of IGF receptors 
ready for the signal generation stimulated by the overexpressed IGF-2. Studies showed that 
blocking of the receptors was able to give antitumoral effect in HCC cells (Nussbaum et al., 
2008). Selective blockage of IGF-IR by monoclonal antibody effectively disrupted IGF 
signaling, reduced cell viability and proliferation. The inhibition of IGF-IR signal initiation 
was able to delay tumor growth and prolonged survival in vivo (Tovar et al., 2010). With 
understanding of IGF signaling mechanism in HCC, it is possible to employ various 
strategies to effectively inhibit IGF signaling, and in turn suppress cell proliferation and 
increase apoptosis in HCC. 
2.2 mTOR pathway 
mTOR pathway is a downstream growth signal induced by EGF and IGF signaling, and is 
coupled with PI3K/AKT pathway. mTOR pathway has an important role in the 
www.intechopen.com
 
Novel Therapeutic Targets for Hepatocellular Carcinoma Treatment 
 
37 
pathogenesis of HCC, where aberration of mTOR pathway was seen in 15% to 41% of HCC 
cases ranged from 15% to 41% (Hu et al., 2003). In HCC, the commonly hyperactive EGF and 
IGF signaling is responsible for the induction of PI3K/AKT/mTOR pathway, promoting 
tumor progression. The mTOR signaling is mediated by mTOR complex 1 and 2 (mTORC1 
and mTORC2). mTORC1 is comprised of mTOR, regulatory associated protein of mTOR 
(RAPTOR), and mammalian LST8/G-protein ǃ-subunit–like protein. mTORC1 is a 
downstream signal of AKT, and has a pivotal role in regulating cell growth and 
proliferation. mTORC1 activates S6 kinase to regulate protein synthesis and induces cell 
cycle to proceed from G1 to S phase (Bjornsti and Houghton, 2004).  
Besides, mTOR is also the subunit of mTORC2 which consists of a protein RAPTOR-
independent companion of mTOR (RICTOR), and proline-rich protein 5/G-protein ǃ-
subunit–like protein. Unlike mTORC1 which is inducible by AKT, mTORC2 plays a critical 
role in the phosphorylation and activation of AKT (Sarbassov et al., 2005). The 
serine/threonine kinase AKT acts as a cytoplasmic regulator of numerous signals. It is 
shown that AKT is frequently amplified and overexpressed in various cancers, and it 
demonstrates significant oncogenic properties in diverse cancer types. In homeostasis 
condition, AKT is negatively regulated by the tumor-suppressor PTEN. However, increased 
activation of AKT is often observed, because PTEN is frequently lost in cancers including 
HCC. Other than mTORC1, AKT regulates a wide-spectrum of targets such as cyclin D1 and 
MDM2/p53 (Vivanco & Sawyers, 2002). In HCC, aberration of mTORC2 enhances AKT 
activity, induces downstream AKT targets and promotes tumorigenesis. One can see that 
the AKT regulating effect of mTORC2 is as important as mTORC1 within the 
PI3K/AKT/mTOR pathway. 
Recently, it is suggested that the PI3K/AKT/mTOR pathway can be a major molecular 
target in cancer remedy. As a critical player in the mTOR signaling, the activity of mTOR 
often increases in HCC. Blockage of mTOR-mediated signaling showed antineoplastic 
activity in different experimental models of HCC. The use of mTOR inhibitors could reduce 
cell proliferation in vitro, and decrease tumor growth in xenografted mouse model 
(Villanueva et al., 2008). mTOR inhibitors such as sirolimus and everolimus demonstrated 
potent antitumor properties. Encouraging results were obtained when both mTOR inhibitors 
were studied in clinical trials, either as a single agent or as adjuvant. Furthermore, components 
in the mTOR complexes can also be the therapeutic targets. High level of RICTOR is correlated 
to early recurrence in HCC, and siRNA knockdown of RICTOR reduces HCC cells viability 
(Villanueva et al., 2008). Disruption of mTOR complexes might have additive benefit along 
with mTOR inhibition to abrogate mTOR pathway in treating HCC.  
3. Cell-surface protein 
3.1 Glypican-3 
Glypican-3 (GPC3) is a protein anchored to the cell surface by a glycosyl-
phosphatidylinositol link. Glypican-3 is highly expressed in HCC, and plays a role in 
stimulating various tumorigenic signaling pathways. GPC3 is specifically expressed in 
HCC, but not in cholangiocarcinoma or normal liver tissue. More than 70% of HCC tumors 
were observed with high GPC3 level compared to normal liver tissues (Hsu et al., 1997). 
Consistent with the high GPC3 protein expression found in clinical samples, numerous 
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HCC cell lines have high expression level of GPC3 (Midorikawa et al., 2003). In addition, 
GPC3 expression is correlated with the prognosis of HCC, where GPC3-positive HCC 
patients have a significantly lower 5-year survival rate than patients who are GPC3-negative 
(Shirakawa et al., 2009). 
One of the GPC3 tumorigenic roles is the activation of Wnt/ǃ-catenin signaling. It is shown 
that GPC3 is able to interact with Wnt ligands, and induces canonical Wnt-signaling to 
trigger the stabilization of ǃ-catenin and induction of cyclin D1 (Capurro et al., 2005). The 
heparin sulfate chain of GPC3 is reported to bind with basic growth factors such as FGF-2. 
The interaction between GPC3 and FGF-2 is frequently observed in HCC cells, and is 
responsible for phosphorylation of ERK and AKT (Midorikawa et al., 2003). This interaction 
plays a role in the increase of HCC cell proliferation, and growth of tumor in nude mouse 
model. Additionally, GPC3 interplays with hedgehog signaling in regulating developmental 
growth (Capurro et al., 2008). Though yet to be elucidated, the GPC3-hedgehog signaling is 
suggested to contribute to HCC development. 
Targeting GPC3 and its related growth signaling is a relevant approach to inhibit HCC 
growth. Inhibition of the interaction between GPC3 and Wnt or FGF-2 should theoretically 
reduce HCC growth (Capurro et al., 2005; Midorikawa et al., 2003). GPC3 is also a useful 
target in immunotherapy against HCC. The therapeutic monoclonal antibody against GPC3 
has been developed which could induce antibody-dependent HCC cytotoxicity. Targeting 
GPC3 is able to inhibit tumor growth of HCC cell line xenograft (Ishiguro et al., 2008). Study 
also showed the concomitant treatment with GPC3 monoclonal antibody and sorafenib was 
more potent in preventing tumor growth than sorafenib alone in the HepG2 xenograft 
model (Ishiguro et al., 2008). It is likely that targeting GPC3 could provide great clinical 
benefit during HCC management.  
3.2 Cadherin 17 
Cadherins are important cell adhesion molecules strongly associated with cancer 
progression. Downregulation of E-cadherin (Du et al., 2009) and overexpression of P-
cadherin are often observed in advanced tumor which processes crucial cellular event like 
epithelial-mesenchymal transition (Sun et al., 2011). Cadherin 17 (CDH17) is another 
adhesion molecule upregulated in HCC, and it is linked to the tumorigenesis in various 
gastrointestinal regions (Wang et al., 2005). The upregulation of CDH17 is capable of 
transforming premalignant liver progenitor cells into liver carcinomas in mice. While forced 
expression of CDH17 promoted tumor growth from hepatic progenitor cells, silencing of 
CDH17 reduced the aggressiveness of metastatic HCC cells (Liu et al., 2009). Knockdown of 
CDH17 by RNA-interference decreased the proliferation rate of HCC cell lines despite their 
metastatic potential in vitro and in vivo. It is shown that targeting CDH17 can concurrently 
inactivate Wnt/ǃ-catenin signaling and reduce cyclin D1 level, leading to both growth 
inhibition and cell death. Inhibition of CDH17 results in the re-localization of nuclear ǃ-
catenin to the cytoplasm so as to attenuate the Wnt/ǃ-catentin signaling (Liu et al., 2009).   
Multiple isoforms of CDH17 protein are present in the HCC samples, and it is found that the 
isoform lacking exon 7 is the most abundant in HCC samples (Wang et al., 2005). CDH17 
isoform lacking exon 7 cannot be found in normal liver tissue whereas it is present in about 
50% of human HCC and 30% of premalignant tissues. Detection of this CDH17 isoform was 
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strongly correlated with the prognosis of HCC patients, predicting a shorter overall survival 
rate as well as higher relapse rate and venous infiltration after surgery (Wang et al., 2005). This 
CDH17 isoform, together with others that are exclusively expressed in HCC, might contribute 
to the pathogenesis of HCC. Strategy to target the isoforms of CDH17 allows specifically 
aiming malignant cells rather than the normal hepatocytes. All available evidences suggested 
that targeting CDH17 might be a prospective molecular-based therapy in HCC. 
4. Metabolic pathway 
4.1 Arginine metabolism 
Arginine content is well-known to affect transplanted tumor in mice. Enhanced in vivo 
tumor growth is observed when mice were fed with diet rich in arginine. On the other hand, 
depletion of arginine from their diet inhibits the growth of metastatic tumor (Gonzalez & 
Byus, 1991). It is later proved that arginine is essential for the survival of cancer cells. Cancer 
cells are dependent on exogenous arginine for growth because most of them cannot 
synthesize their own and become auxotropic for arginine (Dillon et al., 2004). There are 
various explanations for the acquisition of arginine auxotropic phenotype in various cancer 
cells, but generally it is associated with the downregulation of argininosuccinate synthase 
(ASS) (Dillon et al., 2004). Arginine auxotrophy is also a common phenomenon in HCC cells 
due to their lackage of ASS (Ensor et al., 2002).  
In somatic cells, deficiency of arginine puts cell cycle on hold, and cells enter the quiescence 
G0 phase. They can tolerate the depletion of arginine for weeks and return to normal 
condition once the arginine content is resumed. On the other hand, arginine deficiency is not 
sustainable in cancer cells (Delage et al., 2010). Defect in cell cycle checkpoint drives 
continuous cell proliferation even with insufficient arginine, but arginine is necessary for 
metabolic and enzymatic pathways in malignant cells. In essence, cancer cells with shortage 
of ASS rely heavily on exogenous arginine. If the uptake of arginine is disrupted, or the 
stability of arginine is lowered, cell death will occur due to a loss of gross balance (Delage et 
al., 2010). This physiological difference between normal and cancer cell makes the arginine 
metabolic pathway a potent target in treatment to distinguish HCC cells from normal cells. 
Reducing arginine stability is one of the strategies against malignant cells, and arginine-
degrading enzyme is the major group of enzymes that can serve the purpose in depleting 
internal arginine. Arginase belongs to such group of enzyme which is responsible for 
arginine degradation in the urea cycle, and its anticancer effect is well documented (Bach et 
al., 1963). In addition to arginase, the enzyme arginine deiminas is proved to efficiently 
deplete cellular arginine in vitro and in vivo (Cheng et al., 2007). Recombinant arginine-
degrading enzymes were developed, and their anticancer effect was investigated in HCC. 
Satisfactory result was obtained using recombinant arginase and arginine deiminas to 
combat ASS-deficient tumors (Izzo et al., 2004). Studies are conducted to improve the 
efficacy of these arginine-degrading enzymes. Modification such as pygelation can increase 
the half-life of the enzyme and prolong its activity. Phase III trial deploying a pegylated 
form of recombinant ADI is undertaken in HCC patients who have failed prior systemic 
treatment. It is also reported that a modified recombinant human arginase is able to inhibit 
ASS-positive HCC, and inhibit tumor cell growth (Cheng et al., 2007).  
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4.2 GLUT1-mediated anaerobic glycolysis 
Due to the high proliferation rate and cell motility rate, the energy requirement of malignant 
cells is immense. It is suggested that malignant cells have their metabolic rate accelerated in 
order to accommodate the excess energy consumption, and glucose is the basic unit 
necessary. Like most cancers, HCC has high glucose requirement and is observed with an 
increase of glucose metabolism. While glucose metabolism in eukaryotic cells has multiple 
levels of control, transport of glucose across the cell membrane is the first rate limiting step. 
Indeed, accelerated glucose metabolism in cancer cells has been associated with increased 
expression of glucose transporter proteins. In HCC, increase uptake of glucose is mediated 
by glucose transporter GLUT1. GLUT1 expression is elevated in hypoxic conditions, and 
this elevates the rate of anaerobic glycolysis which is a metabolic event frequently observed 
in HCC (Amann et al., 2009). Level of GLUT1 determines the rate of anaerobic glycolysis, 
affects glucose uptake and utilization, and plays a role in metastasis, chemoresistance and 
immunity evasion.  
Increased GLUT1 expression is observed in all HCC cell lines compared with primary 
hepatocytes, and this increase could be found in a subset of HCC patients (Amann et al., 
2009). It is demonstrated that suppression of GLUT1 expression by siRNA significantly 
impaired the tumorigenicity of HCC cells. Inhibition of GLUT1 could decelerate anaerobic 
glcolysis, implied by the reduction of both glucose uptake and lactate secretion (Amann et 
al., 2009). RNAi-mediated targeting of GLUT1 is a potent way to combat cancer cells as 
shown in the study of gastric cancer and laryngeal cancer. GLUT1 is possibly a druggable 
target as it is shown that the ATP-binding site is important for the conformation and 
transporter affinity (Liu et al., 2001). Several substances have demonstrated the ability to 
inhibit GLUT1 and cause cancer cell death (Martin et al., 2003). To increase the GLUT1 
targeting specificity, derivatives of the GLUT1 inhibitors were generated and showed 
promising anticancer effect (Morris et al., 1991).  
Glucose analogues or glucose conjugates also serve to inhibit anaerobic glycolysis. Glucose 
analog such as 2-Deoxyglucose reduced the proliferation rate of many hepatoma cells 
(Ingram et al., 2006), and showed enhanced anticancer effects in combination with 
conventional chemotherapeutic drugs such as adriamycin or paclitaxel in xenografted mice 
(Maschek et al., 2004). The use of ketogenic diets is an alternative strategy to target the 
anaerobic metabolism, which is based on a high fat and low carbohydrate diet and mimic 
the metabolic state of fasting (Zhou et al., 2007). As a result, a reduction of carbohydrate 
intake occurs which allows ketones as an alternative fuel for normal tissue. All in all, 
disruption of critical metabolic pathways in HCC cells or targeting the main components of 
the pathways might become alternative therapeutic strategies. 
5. Protein folding and turnover 
5.1 Heat shock protein 90 
Heat shock protein 90 (HSP90) belongs to a highly conserved family of molecular 
chaperones. It plays a role in protein homeostasis by controlling the stabilization and 
activation processes of different proteins (Pearl et al., 2008). HSP90 level is often increased in 
various tumors, which is associated with the continuous protein translation and cell 
proliferation during stress condition (Workman et la., 2007). Upregulation of HSP90 is often 
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associated with increased cyclin-dependent kinase 4 activity, and both were believed to 
contribute to HCC development (Pascale et al., 2005). HSP90 is involved in the folding and 
activity of many bona fide oncoproteins in tumor cells, maintaining their dysregulated 
expression and mutational status. Subsequently, tumor cells become sustainable for cell 
growth and survival, and equip with crucial aberrations required for metastasis (Whitesell 
& Lindquist, 2005). 
HSP90 is proved to be an efficacious therapeutic target in HCC. Inhibition of a broad-
spectrum tumorigenic mechanism is resulted when HSP90 is targeted in vitro and in vivo. 
Independent of the etiological background, all HCC cell lines responded to HSP90 inhibition 
similarly with increased cell cycle arrest and apoptosis (Breinig et al., 2009). It might due to 
the fact that HSP90 inhibition triggered a simultaneous degradation of various 
hepatocarcinogenesis driving factors. In vivo studies showed that inhibitor of HSP90 is 
tumor-cell specific, and is able to efficiently reduce HCC tumor growth. Newly developed 
HSP90 inhibitor showed a lack of significant hepatotoxicity and is more tolerated, which 
become more practical in therapeutic treatment (Breinig et al., 2009). HSP90 inhibition 
further prevents tumor growth by disruption of tumor angiogenesis, as demonstrated by 
blocking PDGFR-ǃ expression in vascular smooth muscle cells and VEGF2 expression on 
endothelial cells (Lang et al., 2009). Moreover, the combinatory use of HSP90 inhibitor and 
other anticancer agents is proved to be beneficial. Blockage of HSP90 is able to enhance the 
antitumor effect of mTOR inhibitor rapamycin by blocking the alternative AKT signaling 
induced by rapamycin (Lang et al., 2009). Inhibition of HSP90 can be invaluable clinically 
during HCC treatment, either by targeting HSP90 alone or in combination with other 
anticancer agent. 
5.2 Ubiquitin-proteasome system 
The ubiquitin-proteasome system plays a crucial role in maintaining cellular homeostasis 
such as regulation of the cell cycle, apoptosis, receptor signaling and endocytosis. 
Aberration in different ubiquitin-proteasome systems is recognized as the fundamental 
cause of various human diseases including cancer. The dysregulation of NF-κB in HCC is 
one of the oncogenic events induced upon defect in ubiquitin-proteasome system. It is also 
observed proteins expressed by HBV (Hu et al., 1999) and HCV (Munakata et al., 2005) are 
reported to cause the alteration of different ubiquitin-proteasome systems, contributing to 
viral replication, hepatotumorigenesis and impairment of host immunity. These findings 
demonstrate the importance of an intact ubiquitin-proteasome system in preventing HCC 
development (Chen, 2005). In the United States, a proteasome inhibitor bortezomib is used 
clinically to manage late-stage multiple myeloma (Chauhan et al., 2008). Studying the 
mechanisms of various ubiquitin-proteasome systems not only enable a better 
understanding of cancers, but also help to explore new strategies to cancer management. 
5.2.1 Gankyrin 
In human HCC, a small proteasome regulatory subunit called gankyrin is frequently over-
expressed at both mRNA and protein levels. A study showed gankyrin expression levels 
were highly upregulated in hepatoma cell lines, and its level was higher in HCC samples 
compared to normal livers, and premalignant or cirrhotic livers (Higashitsuji et al., 2000). 
Gankyrin is found to interact with retinoblastoma, increasing its phosphorylation level so as 
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to reduce cellular retinoblastoma stability (Li et al., 2005). In addition, gankyrin increases 
both the association and activity of MDM2 for p53. This inactivates p53 by increasing the 
ubiquitylation level of p53 and in turn driving proteasomal degradation of p53 (Higashitsuji 
et al., 2005). Gankyrin also promotes HCC growth through the activation of oncoprotein D 
cyclin-dependent kinase 4 (CDK4). The activity of the kinase is negatively regulated by p16 
during stress condition, but this inhibitory effect is removed when gankyrin competes with 
p16 for the binding of CDK4 and thus allows the activation of CDK4 (Dawson et al., 2002). 
Other than tumor promoting effect, gankyrin contributes to cancer drug resistance. It 
desensitizes cancer cells to the effect of DNA-damaging chemical agents by preventing p53-
dependent apoptosis (Higashitsuji et al., 2005).  
The use of RNAi to knock down gankyrin in HCC resulted in a decrease of cell growth, as 
well as reduction in observed levels of hyperphosphorylated retinoblastoma (Li et al., 2005) 
and restoration of caspase 8/9-dependent apoptosis (Higashitsuji et al., 2005). Silencing of 
gankyrin expression also reportedly attenuated epithelial to mesenchymal transition 
together with cell migration and invasion. The inhibition of gankyrin also reduced the level 
of nuclear ǃ-catenin (Dong et al., 2011), c-myc, cyclin D1 (Fu et al., 2011) and insulin-like 
growth factor binding protein 5 (Umemura et al., 2008). The close relationship with several 
pro-tumorgenic events makes gankyrin a rationale target during HCC treatment. 
5.2.2 X-linked inhibitor of apoptosis 
X-linked inhibitor of apoptosis (XIAP) belongs to the inhibitor of apoptosis (IAP) domain-
containing family, and is famous of its anti-apoptotic ability. They are induced by NF-κB 
signaling to circumvent the pro-apoptotic effect induced by JNK pathway (Kaur et al., 2005), 
by inhibiting caspase-mediated apoptosis. Apart from this, XIAP participates in the 
regulation of transforming growth factor ǃ (TGF-ǃ) -induced apoptosis through an ubiqutin-
proteasomal regulating machine. XIAP is able to complex with TGF-ǃ activated kinase 1 
(TAK1), as such this negatively regulates the TGF-ǃ signaling (Chen, 2005). The RING domain 
of XIAP is responsible for the poly-ubiquitylation of TAK1, resulting the proteasome-mediated 
degradation of TAK1. Subsequently, it disrupts the activation of JNK signaling and halts 
apoptosis. It is speculated that the involvement of XIAP in HCC is common given that most 
HCCs acquire resistance to TGF-ǃ-mediated cell killing (Chen, 2005). Moreover, TAK1 is 
important for the phosphorylation and activation of the IKK complex. Increased activity of 
IKK leads to the degradation of the IκB-ǂ inhibitor of NF-κB and subsequent activation of 
classical NF-κB signaling. Activation of IKK also causes the degradation of MKK7, the 
upstream kinase essential for activation of JNK signaling. Reduction of MKK7 level could 
ablate the JNK signaling and inhibit apoptosis (Kaur et al., 2005).  
Inhibition of XIAP sensitizes HCC cells to apoptotic signal owing to retaining of TAK1. In 
doing so, persistent activation of JNK signaling is resulted whenever the TGF-ǃ-mediated 
apoptotic signal is induced. Stabilized TAK1 also potentially attenuate the influence of NF-
κB signals (Chen, 2005). Besides, it is reported XIAP inhibition in HCC enhanced TRAIL-
mediated cell killing. The combination of XIAP silencing shRNA and tumor-necrosis factor-
related apoptosis TRAIL is reported to generate potent antitumor effect in HCC cells and 
tumors in animal models (Pan et al., 2008). Targeting XIAP further renders HCC cells 
vulnerable to other therapeutic effect by releasing the break for caspase-mediated apoptosis 
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(Deveraux et al., 1997). All in all, inhibition of XIAP or blockage of interaction between XIAP 
and TAK1 may be one of the best HCC management strategies.  
6. HCC tumor microenvironment 
It is gradually accepted that the progression and aggressiveness of cancer cells are defined 
by the tumor-stromal interaction. In HCC, the tumor microenvironment plays a pivotal role 
in affecting cancer development. Through paracrine and autocrine mechanisms, the stromal 
components communicate with the tumor, promoting the HCC cell proliferation, survival, 
and allowing them to invade and metastasize. In the past, majority of targeting therapies are 
derived from the research focusing on intracellular events of cancer cells. However, limited 
studies are able to be translated into effective therapies, because they ignored the influence 
from the surrounding components. Although the field is still in its embryonic stage waiting 
to be explored, targeting the interaction between tumor-stromal may be a more logical 
approach against HCC. 
6.1 Hepatic stellate cells 
Stromal remodeling occurs routinely during the development of hepatic fibrosis, cirrhosis 
and HCC, featured with the infiltration of activated hepatic stellate cells (HSC). Upon 
hepatic injury, HSCs is stimulated and transformed to acquire an activated myofibroblast-
like phenotype that is responsible for the excessive hepatic matrix deposition in chronically 
damaged livers. They are densely located in tumor sinusoids, fibrous septa and HCC- 
generated capsule. Activation of HSC is recognized as a key event during 
hepatotumorigenesis (Zhao et al., 2011).  
Activated HSCs considerably increase the activity of NF-κB and ERK in HCC. It is known 
that both NF-κB and MAP kinase/ERK pathways are involved in the progression of human 
HCC, and they induce the proliferation of HCC cells, and protect HCC cells from apoptosis 
(Amann et al., 2009). The paracrinal communication between HSC and HCC forms the major 
linkage for the induction of HCC development. Several soluble factors secreted by activated 
HSC are identified to be responsible for the tumorigenic effects. HSC released a substantial 
amount of protumorigenic factors, including the hepatic growth factor (HGF), which 
enhances the invasiveness of HCC cells. The growth and the migration capability of HCC 
were impaired once the binding of HGF to HCC cells was disrupted (Barnaeva et al., 2007). 
Other studies demonstrated that TGF-ǃ secreted by HSC accelerated tumor progression in 
neoplastic hepatocyte (Sano et al., 2005). TGF-ǃ was able to induce epithelial to 
mesenchymal transition and augment PDGF signaling in oncogenic Ras-transformed 
hepatocyte. It is believed that a combination of HSC-released growth factors consisting of 
FGF-1 and -2, PDGF and IGF are responsible for promoting HCC tumorigenesis (Bataller & 
Brenner, 2005). The emerging evidences support that the activated HSC/myofibroblasts in 
tumor microenvironment have huge impact on HCC development and progression, and this 
stromal components should be regarded as one of the primary targets in HCC therapy. 
6.2 Heparan sulfate proteoglycan modulating enzymes 
Heparan sulfate proteoglycans (HSPG) play important biological roles in both cellular and 
extracellular context, contributing to the proper communication between cells and their 
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surrounding components. While extracellular HSPGs function to maintain extracellular 
matrix (ECM) self assembly and integrity with other ECM molecules, cell surface HSPGs are 
responsible for the binding of growth factors, chemokines, cytokines and enzymes. In 
addition to normal biological process, HSPGs also influence a number of pathological events 
including inflammation, tumor growth, metastasis and angiogenesis.  
6.2.1 Heparanase 
Evidences suggested that the expression of heparanase, an enzyme that degrade the side 
chain heparin sulfate, is closely related to tumor invasion, angiogenesis and metastasis in 
HCC (El-Assal et al., 2001). Heparanase level is high both in HCC patient serum and tumor 
tissues. Heparanase level in serum is linked with the aggressiveness of HCC (Wang et al., 
2010), and that in tumors is positively correlated with tumor size, staging and portal vein 
invasiveness (El-Assal et al., 2001). It is speculated that the major pro-tumorigenic effect of 
heparanase is derived from the ability to cleave HSPG, resulting in the release of HS-bound 
molecules such as ECM digesting enzymes and angiogenic factors. Consequent ECM 
degradation and angiogenic factor released combine to construct a microenvironment 
favorable for HCC cell migration and invasion (Zhang et al., 2007). 
Extensive cleavage of heparin sulfate might release other cell surface bound factors such as 
growth factors and chemokines that potentially generate diverse biological effects in both 
autocrine and paracine manners. Upregulation of heparanase is associated with increased 
releasing of basic fibroblast growth factor (bFGF). bFGF released in this way contributes to 
tumor progression through the activation of oncogenic signaling and construction of a 
favourable tumor niche (Zhao et al., 2006).  
Targeting heparanase provides a novel perspective in managing HCC by modulating the 
tumor-stromal communication. Knocking down of heparanase can significantly inhibit the 
invasiveness, metastasis, and angiogenesis of HCC cell both in vitro and in vivo (Zhang et 
al., 2007). Several molecule inhibitors of heparanase can also attenuate the progression of 
hepatoma cells. The antitumor effect is possibly generated by preventing the degradation of 
ECM and basal membrane. Another study showed inhibiting heparanase could effectively 
stop the release of bFGF so as to inactivate the bFGF signaling effect and suppress 
subsequent angiogenesis (Zhao et al., 2006). These findings have gradually switched the 
attention in cancer therapy research, from focusing solely in intracellular targets to the 
interplay between cancer cells and the surrounding microenvironment. 
6.2.2 Sulfatase 2 
Another important feature of heparin sulfate chains is related to its substrate binding 
capacity. 6-O-sulfation, a type of heparin sulfate modification, is known to play a specific 
role in modulating ligand binding. The enzyme SULF2 is a member of the sulfatase family 
that modulates critical cellular signaling pathways by the removal of 6-O-sulfation 
(Morimoto-Tomita et al., 2002). In contrast to another sulfatase member tumor suppressor 
SULF1, SULF2 has an oncogenic role in cancer, and its expression is elevated in HCC. 
Upregulation of SULF2 is observed in 57% HCC tissues and 73% HCC cell lines. Level of 
SULF2 is positively correlated with a more aggressive tumor phenotype and poorer patient 
survival (Lai et al., 2008). Ectopic expression of SULF2 promoted cell proliferation and 
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migration in various HCC cell lines, and enhanced tumor growth in vivo. The tumorigenic 
effect of SULF2 is partially brought by the induction of the aforementioned pro-cancerous 
glypican-3 expression. It was found that SULF2 enhanced the binding of FGF2 to the cancer 
cell and activated FGF signaling in a glypican-3 dependent manner (Lai et al., 2008). In 
addition, SULF2 increased cell surface glypican-3 and Wnt3a level in HCC, leading to the 
increase of glypican-3-dependent Wnt/ǃ-catenin signaling (Lai et al., 2010). 
SULF2 is a rational target in HCC therapy as suggested by several SULF2 knockdown 
studies. RNAi-induced suppression of SULF2 reduced the cell growth and migration in cell 
lines with high SULF2 expression (Lai et al., 2010) in vivo and in vitro. Knockdown of 
SULF2 was able to reduce the expression of GPC3, as well as the activity of FGF signaling by 
blocking FGF2 binding (Lai et al., 2008). Reduction of GPC3 also downregulates Wnt3a 
expression, and attenuates the Wnt/ǃ-catenin signaling with reduced phosphorylated 
GSK3-ǃ and ǃ-catenin. Given the relationship between SULF2 and GPC3, it is worthwhile to 
investigate the clinical benefit in targeting SULF2 in HCC treatment. Furthemore, SULF2 
protects against caspase 3 and 7 mediated apoptosis induced by PI3K, ERK and JNK 
inhibitor. Inhibition of SULF2 re-sensitized HCC cells to the drug-induced apoptosis by 
reducing phosphorylation of AKT, downregulation of cyclin D1 and anti-apoptotic BCL-2, 
as well as upregulation of pro-apoptotic BAD (Lai et al., 2010). The findings might have 
implication to develop combinatory treatment against drug-resistant HCC. 
7. Epigenetic modulator 
Abnormal epigenetic events are frequently observed in HCC, which can alter gene 
expression through modification of histone tails or DNA. The major players contributing to 
these aberrations such as DNA methyltransferase and histone deacetylase are under 
intensive investigations. In fact, there are many other players involved during the 
establishment of aberrant epigenetic status. Among them, polycomb repressive complexes 
(PRC) are catching more attention recently due to their significant roles during cancer 
development via suppression of various tumor suppressor genes (Steele et al., 2006). In 
human, there are two polycomb repressive complexes namely PRC1 and PRC2. Despite 
their unique gene repression mechanism, both of them are frequently involved in the 
oncogenesis of HCC. Targeting of epigenetic modulators in theory generates persistent 
effects on tumors as heritable changes are induced. Such an approach is superior to 
targeting other molecular players that only bring out transient effects.  
7.1 BMI1 
PRC aroused increasing attention recently as they are shown to contribute heavily in the 
maintenance of stem cell and the determination of cell fate. BMI1 is a critical component of 
PRC1 in mediating the ubiquitination of histone in order to regulate local gene expression. 
BMI1 is not detected in normal hepatocyte but is overexpressed in HCC. Dysregulation of 
BMI1 is speculated to promote activation of cancer stem cell in HCC. BMI1 has a higher 
basal level in the side-population (SP) cell where such a subgroup of cancer cells is 
characterized by the ability to exclude Hoechst 33342 dye via the ABC cassette transporter. 
This subpopulation is believed to harbor stem cell properties, and BMI1 is shown to play a 
crucial role in their self-renewal process (Chiba et al., 2008).  
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BMI1 mediates stemness features in HCC cells. In HCC, SP cells expressing BMI1 showed 
enhanced tumorigenic potential compared to the corresponding non-SP cells. Knockdown of 
BMI1 markedly abolished the tumor-initiating ability of SP cells in non-obese 
diabetic/severe combined immunodeficiency mice, leading to a 100 fold decrease of 
tumorigenic activity (Chiba et al., 2008). Such decrease in tumorigenic activity was 
accompanied with a reduction of SP cell number in different HCC cell lines. It is shown that 
BMI1 mediates the suppression of INK4A/ARF and drives self-renewal. Inhibition of BMI1 
resulted in the derepression of INK4A/ARF, and in turn disrupted self-renewal in SP cells, 
hence suppressed SP cells survival upon long time culture. BMI1 additionally regulates 
diverse cellular processes including cell cycle, apoptosis and senescence by the repression of 
the INK4A/ARF expression (Xu et al., 2009).  
Since there are numerous targets of BMI1 in human genome, it is predictable that the 
oncogenic effect of BMI1 should not simply depend on INK4A and ARF repression. BMI1 
was able to cooperate with activated RAS to transform hepatocytes into malignant cells (Xu 
et al., 2009). Furthermore, BMI1 expression in HCC is significantly associated with the 
expression of ABC transporter B1 (ABCB1) which was consistently reported to generate the 
multiple drug-resistant phenotype (Effendi et al., 2010). It is possible that one of the 
downstream targets of BMI1 is ABCB1. The ability to eliminate cancer progenitor cell in 
HCC by BMI1 inhibition is a potent anticancer mediation, and potentially provides a cure 
for HCC patients.  
7.2 EZH2 
Polycomb repressive complex 2 (PRC2) is another modifier of the chromatin structure, 
which determines the activity of gene expression. PRC2 primarily regulates gene expression 
by inducing the methylation on lysine 9 and lysine 27 of histone 3, and plays important roles 
during development and tumorigenesis. In this complex, EZH2 is the catalytic subunit 
directly involves in transferring methyl-group to the histone tails (Kirmizis et al., 2004). The 
level of EZH2 is important in determining the PRC2 activity in cells. EZH2 regulates cell 
proliferation, and its expression is often augmented during tumorigenesis. EZH2 
overexpression can be observed in many cancers, including prostate, breast and pancreas 
cancer, and most often high level of EZH2 is correlated to aggressiveness of the 
malignancies (Tsang et al., 2011). EZH2 is rarely detected in normal hepatocytes, but is 
frequently detected in HCC cell lines and HCC tissues (Chen et al., 2007).  
EZH2 is involved in numerous cellular processes and signaling pathways and evidences 
suggested that EZH2 promotes cancer development by repressing diverse tumor-
suppressors. Recently, EZH2 reportedly activated Wnt signaling in HCC. Concurrent 
overexpression of EZH2 and ǃ-catenin was observed in more than 30% of human HCC, 
which is associated with tumor progression (Cheng et al., 2011). In HCC cells, EZH2 is 
found to frequently occupy the promoter of numerous Wnt pathway antagonists. As such, 
these antagonists are silenced, relieving the inhibitory effect on Wnt/ǃ-catenin signaling. In 
immortalized hepatocytes, ectopic expression of EZH2 activated Wnt/ǃ-catenin signaling 
and triggered cell proliferation (Cheng et al., 2011). Conversely, downregulation of EZH2 
inhibited ǃ-catenin signaling, resulting in the retardation of HCC cell growth. Study showed 
that knockdown of EZH2 by lentivirus-based shRNA inhibited tumor growth in vivo (Chen 
et al., 2007), demonstrating a potent effect against HCC by targeting EZH2. The significance 
www.intechopen.com
 
Novel Therapeutic Targets for Hepatocellular Carcinoma Treatment 
 
47 
of EZH2 role in HCC suggested that strategies built around EZH2 is definitely 
advantageous. 
EZH2 is theoretically suitable for pharmalogical targeting as it contains a SET domain 
responsible for the histone methyltransferase activity. Targeting of the enzymatic domain is 
proved to reduce histone methylation and de-repress expression of tumor suppressor genes. 
In addition to the catalytic domain, there are two N-terminal domains mediating protein-
protein interactions and promoting nuclear localization within EZH protein, which are 
druggable targets in ablating EZH2 activity. Disruption of the PRC2 is also effective to 
attenuate the tumorigenic effect of EZH2. The formation of functional PRC2 requires other 
protein subunits such as EED and SUZ12. Report revealed that the use of agent disrupting 
PRC2 subunits is a relevant way to affect PRC2 function (Tan et al., 2007). Although 
currently there is no EZH2 specific inhibitor, but agent such as DZnep is also able to deplete 
the cellular EZH2, inhibit EZH2 functions and lower the H3K27 trimethylation level (Chiba 
et al., 2011). This fundamental knowledge surely enables researchers to design potent agents 
to target EZH2 in HCC. 
8. Non-coding RNA 
8.1 MicroRNA 
MicroRNAs are small non-coding RNAs that regulate the translation of many genes. They 
not only regulate normal cell development but also play important roles in cancer 
development and progression by affecting cell survival, angiogenesis and metastasis. Many 
studies illustrated the potential of manipulating microRNA expression in cancer therapy. It 
is believed that microRNA-based remedy can have a huge impact on cancer cells, as they 
regulate whole programs of gene expression via suppressing hundreds of genes 
simultaneously (Farazi et al., 2011).  In human HCC, numerous microRNAs are identified to 
give major contributions, either having oncogenic or tumor suppressing ability. Here, those 
microRNAs having great potential as HCC therapeutic targets will be discussed.  
OncomiR is a novel term coined for microRNAs possessing proto-oncogenic effects in 
cancers. In HCC, a number of oncomiRs are identified and their roles are characterized. 
Among them, the roles of microRNA-21 (miR-21) in HCC development were well-
documented (Liu et al., 2010). miR-21 is universally overexpressed in majority of cancers 
and is phenomenally involved in approximately all tumorigenic processes. miR-21 is able to 
induce cell transformation, mediate cancer cell growth, cell cycle and self-renewal, prevent 
apoptosis, promote metastasis and generate drug-resistance (Liu et al., 2010). High 
expression of miR-21 is correlated with advanced tumor stage, frequent metastasis and poor 
patient prognosis. In HCC, miR-21 is overexpressed, and has been proved to promote 
malignant cell growth and spreading by targeting tumor suppressor PTEN and inducing 
FAK phosphorylation (Meng et al., 2007). Furthermore, miR-21 induces resistance to 
anticancer effect of interferon-ǂ and 5-fluorouracil in HCC (Tomimaru et al., 2010). 
Importantly, inhibition of miR-21 is able to reduce the aggressiveness in HCC, and relieves 
the suppressive effect to several tumor suppressor genes targeted. Besides miR-21, targeting 
other oncomiRs such as miR-29 (Xiong et al., 2010) and miR-221 (Pineau et al., 2010) is also 
robust in reversing the malignant phenotypes in HCC. 
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On the other hand, various microRNAs with tumor suppressing capacity are lost or 
underexpressed in HCC. Restoration of their expression in HCC is another effective 
approach against HCC. Previous studies suggested a strong association between low miR-26 
expression and both prognosis and response to interferon therapy in patients with HCC (Ji 
et al., 2009). Low miR-26 expression is highly associated with tumor formation in vivo, and 
replenishing miR-26 in liver tumors with the use of gene therapy could generate potent 
antitumor effects. miR-26a in particular is substantially reduced in MYC-induced HCC (Ji et 
al., 2009). The replacement therapy of miR-26 is considered safe, because miR-26 is 
expressed by most normal cells and is unlikely to be toxic. Other than miR-26, miR-122 is 
significantly downregulated in liver cancer with intrahepatic metastasis. Restoration of miR-
122 reduced cell migration, invasion and colony formation ability in vitro, and 
tumorigenesis, angiogenesis and metastasis in vivo (Coulouarn et al., 2009). Currently, more 
microRNAs with antitumor effect including miR-199a/b-3p were identified and potentially 
play a pivotal role in the combat against HCC (Hou et al., 2011). 
To note, increased activity of RNA-induced silencing complex (RISC) was observed in 
HCC (Yoo et al., 2011). The role of RISC is critical in facilitating activity of RNAi including 
microRNA-mediated target silencing. The components of RISC including AEG-1 and 
SND1 were both overexpressed in HCC, which leads to the hyperactivity of RISC. 
Increased RISC activity resulted in an accelerated degradation of numerous tumor 
suppressor genes that are the target of various oncomiRs. Report showed that inhibition 
of RISC activity by knocking down SND1 abrogated cell growth in HCC cells in vitro and 
in vivo (Yoo et al., 2011). It not only unveils a new microRNA associated pro-tumorigenic 
mechanism, but also provides an additional approach to disrupt microRNA-mediated 
tumorigenic effect during HCC remedy.  
8.2 Long non-coding RNA 
In eukaryotes, there are abundant amount of transcripts which are long in length and lack 
any substantial open reading frame as well as protein coding capacity. Increasing evidences 
suggested that these long non-coding RNAs (lncRNA) play critical role in cellular processes 
such as development, via the modulation of chromatin structure. Some of them possess the 
ability to modulate cancer epigenome and contribute to different pathological conditions 
such as tumor invasion and metastasis. A better understanding in the oncogenic 
mechanisms of lncRNA will unveil a new direction in cancer therapy.  
Highly upregulated in liver cancer (HULC) is an lncRNA that is frequently overexpressed in 
HCC. siRNA knockdown of HULC in HCC cell lines was able to alter the expression of 
genes described in the context of HCC (Panzitt et al., 2007). Reduction of cellular HULC 
upregulated genes participates in diverse biological processes including cell differentiation, 
cell adhesion, protein phosphorylation and tumor suppression. Another study reported that 
HULC was also expressed in metastasized tumor nodules in liver originated from colorectal 
cancer, but not in primary colorectal cancer (Matouk et al., 2009). It suggested that 
expression of HULC might be a pre-requisite for any tumor formed in liver. The importance 
of HULC in HCC is further supported by the observation that HULC expression is strongly 
linked to HBV infection (Matouk et al., 2009). Due to the high specificity of HULC for cancer 
located in liver, it is worthy of studying its potential role in managing HCC. 
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There are two other lncRNAs recently reported to be overexpressed in HCC cell lines and 
tissues, namely the metastasis associated lung adenocarcinoma transcript 1(MALAT-1) and 
HOX transcript antisense RNA (HOTAIR). Both of them have been previously implicated in 
other malignancies regarding their capacity to promote cancer metastasis. In HCC, their 
expression is correlated to the prognosis of the patients which predicts tumor recurrence 
after liver transplantation. Inhibition of MALAT-1 in vitro effectively reduced cell viability, 
motility, invasiveness, and HCC cells became sensitive to pro-apoptotic signal (Lai et al., 2011). 
Similarly, knockdown of HOTAIR decreased cell viability and cell invasiveness, as well as 
sensitized HCC cells to tumor necrosis factor- ǂ induced apoptosis, and cytotoxic effect of 
doxorubicin and cisplatin (Yang et al., 2011). Their roles in HCC progression are important 
which provide a rational base to take into consideration during HCC therapy. 
9. Liver cancer stem cell 
Accumulating evidences support that the development of HCC is based on the cancer stem 
cell (CSC) model. In this hypothesis, there is only a subset of cells within a tumor or in the 
cell pool that sustains malignant growth. Such cellular subset is referred to as the cancer-
initiating cells or cancer-propagating cells (Visvader, 2011). It provides the explanations for 
cancer initiation, local recurrence, metastasis and therapy resistance which raised enormous 
controversies in the past. CSCs have been identified in many cancer types including HCC 
(Mishra et al., 2009). In this regard, CSC should be the principal target of HCC therapy. 
However, conventional methods such as chemotherapy and radiotherapy are ineffective 
because of the CSC resistant properties, as well as their pro-angiogenic effect. Studies are 
vigorously conducted to develop effective methods to extinguish CSC in HCC.  
9.1 Cancer stem cell markers  
Numerous surface markers for HCC stem cells were identified, and they include CD133, 
CD90, CD44, CD13 and EpCAM. Although their roles in liver CSC are unclear, studies 
showed that targeting these markers can specifically harm CSC with high efficacy. It is 
reported that tumorigenicity and invasive capacity of liver CSC were impaired by targeting 
CSC surface marker EpCAM, leading to reduction of CSC pool (Yamashita et al., 2009). 
Besides, inhibition of CD44 in HCC cells could enhance apoptosis, reduce tumorigenicity 
and invasion. Interestingly, isoforms of CD44 are differentially expressed between HCC and 
normal hepatocytes. Targeting of the CD44 isoforms prevalent in HCC was able to 
selectively deplete HCC cells without harming normal cells (Miletti-González et al., 2005). 
Therefore, direct targeting of CSC-specific markers may also be a promising therapeutic 
strategy to eradicate liver CSC.  
9.2 Stemness signaling 
Cancer stem cells share various common characters with somatic and embryonic stem cells. 
Many signaling pathways observed exclusively in stem cells can also be detected in cancer 
stem cells. These signalings include Wnt/ǃ-catenin, Hedgehog and Notch signaling (Mishra 
et al., 2009). Disturbing the signalings involved in normal stem cell fate reportedly 
decreased the self-renewal and proliferating capabilities of CSCs. For example, small 
molecule inhibitor of hedgehog pathway could reduce the likely CSC with progenitor 
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marker aldehyde dehydrogenase in pancreatic cancer (Feldmann et al., 2007); Targeting 
Notch pathway was able to inhibit cancer stem cell self-renewal and decreases tumor 
growth (Cheng et al., 2004); The Wnt pathway can be inhibited by blocking the ǃ-catenin 
interaction with TCF gene, and as such there was a reduction of CSC cells and spheroid 
formation (Lepourcelet et al., 2004). Apart from tumor promoting effects, stem cell 
signalings could induce resistances and recurrences to different cancer therapies in HCC. 
HCC cells survived through radiation, and acquired radioresistance was found to have 
Wnt/ǃ-catenin signaling activated (Woodward et al., 2007). Relapse of HCC after radiation 
was also associated with the induction of Notch and Hedgehog signaling pathways which 
sustained HCC cell self-renewal and tumorigenicity (Clement et al., 2007).  
Recently, the STAT3/IL-6 signaling is revealed as another pathway activated in liver CSC 
and plays an important role in maintaining the liver CSC. Activation of IL-6 pathway is 
suggested to be a consequence of TGF-ǃ signaling defects (Tang et al., 2008). Impaired TGF-
ǃ signaling is a piece of useful information to distinguish liver CSC from normal stem cells. 
Hence, targeting IL-6 pathway might be a specific way to target liver CSC without affecting 
somatic stem cells. STAT3/IL-6 pathway inhibition by small inhibitor is also effective in 
HCC with lesion of TGF-ǃ signaling, attenuating tumorigensis of HCC (He et al., 2004). 
9.3 Differentiation pathway 
Like other cancer types, HCC cells are highly heterogenous. It is believed that liver cancer 
stem cells are the initiator in establishing the heterogenous background of the tumor, whilst 
liver CSC themselves remains undifferentiated (Visvader, 2011). Forced differentiation of 
the CSC in HCC is a relevant approach to deplete the CSC in the cancer cell pool. 
Differentiation of cancer cells into less aggressive forms has been a successful strategy as 
demonstrated in the treatment of acute promyelocytic leukemia. The application of all-trans 
retinoic acid after normal chemotherapy resulted in a 90% remission and 70% cure rate in 
acute promyelocytic leukemia. Differentiation therapy can be an appealing and effective 
treatment against HCC (Massard et al., 2006). 
It is reported that force expression of hepatocyte nuclear factor 4-ǂ (HNF4-ǂ) could promote 
the differentiation of hepatoma cells to normal hepatocytes. Most importantly, there is a 
reduction of stemness genes and a decrease of CD133+ /CD90+ subpopulation during the 
differentiation. HNF4-ǂ is able to induce cell cycle arrest, cell senescense in HCC cells as well 
as the tumorigenic ability in mice (Yin et al., 2008). Systemic and intratumoral administration 
of HNF4-ǂ carrying adenovirus could respectively prevent tumor metastasis and exhibit 
antitumor effect. Understanding the differentiation pathways in liver CSC allows identification 
of key differentiating factors (Yin et al., 2008). Identification of valid differentiation pathways 
in CSC enables scientists to explore a new avenue in countering liver CSC. 
9.4 Cancer stem cell niche 
Other novel ideas for stem cell targeting therapy include the disruption of the tumor niche 
essential for CSC homeostasis (Gokmen-Polar et al., 2008). The specified microenvironment 
where stem cells reside often dictates self-renewal and reproduction. Alteration of stem cell 
niche components can effectively change stem cell fate, as in the case of experimental 
parathyroid hormone induction. Furthermore, human embryonic stem cell–derived 
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fibroblast-like cells provide a supportive environment for stem cells through insulin-like 
growth factor 2 (Martínez-Iglesias et al., 2008). Targeting insulin like growth factor 2 
therefore can manipulate the stem cell microenvironment. Apart from the molecular content 
surrounding liver CSC, there is accumulating evidence that the physical environment is a 
critical mediator of HCC tumor behaviour. The stiffness of matrix is a strong predictor of 
HCC development. Increasing stiffness was found to promote HCC cell proliferation. On 
the other hand, a soft environment induces reversible stem cell characteristics in HCC 
(Schrader et al., 2011). With understanding of critical factors influencing liver CSC, 
comprehensive approach will be developed to eradicate these primary targets in HCC. 
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